The Europe Telmisartan Market would witness market growth of 5.4% CAGR during the forecast period (2020-2026). Telmisartan refers to a group of antihypertensive drugs known as angiotensin receptor blockers (ARBs). Using this medication, hypertension (high blood pressure) can be managed & treated.
It operates by restricting the action of some substances that constrict the blood vessels, allowing the smooth blood flow & the heart to pump more effectively. Telmisartan is also utilized in reducing the possibility of stroke, heart attack, or death in persons 55 years of age or older who are more prone to cardiovascular diseases. Telmisartan comes as a tablet to be consumed by mouth. Telmisartan drug could be utilized alone or combined with other drugs like amlodipine & hydrochlorothiazide. There are three different forms of this tablet.
There is a common & new term attached with lifestyle i.e. sedentary. Due to hectic lifestyles and air-conditioned work environments of corporates, the requirement for people to remain active has decreased considerably. All these factors are likely to increase lifestyle diseases such as diabetes, cardiovascular, and hypertension diseases. While low physical activity will enhance the possibilities of the disease, the increasing population choosing bad habits such as smoking and alcohol with an aim to relax the nerves would increase the cases of cardiovascular diseases. Telmisartan is utilized in the treatment of all these mentioned conditions. With the rising number of patients, consumption of telmisartan is anticipated to witness a hike during the forecast period.
The Germany market dominated the Europe Online Pharmacies Market by Country in 2019, thereby, achieving a market value of $24 million by 2026. The UK market is exhibiting a CAGR of 5% during (2020 - 2026). Additionally, The France market is poised to grow at a CAGR of 7.4% during (2020 - 2026).
Based on Indication, the market is segmented into Hypertension and Cardiovascular Risk Reduction. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: Telmisartan Market in Europe is expected to register a CAGR of 5.4% during the forecast period (2020-2026)
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Aurobindo Pharma Limited, Boehringer Ingelheim International GmbH, Cipla Limited, GlaxoSmithKline PLC (GSK), Mylan N.V., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., and Cadila Healthcare Ltd. (Zydus Cadila).
Scope of the Study
Market Segments Covered in the Report:
By Indication
- Hypertension
- Cardiovascular Risk Reduction
By Distribution Channel
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Pharmacies
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Aurobindo Pharma Limited
- Boehringer Ingelheim International GmbH
- Cipla Limited
- GlaxoSmithKline PLC (GSK)
- Mylan N.V.
- Sanofi S.A.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Cadila Healthcare Ltd. (Zydus Cadila)
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Telmisartan Market, by Indication
1.4.2 Europe Telmisartan Market, by Distribution Channel
1.4.3 Europe Telmisartan Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Europe Telmisartan Market by Indication
3.1 Europe Hypertension Market by Country
3.2 Europe Cardiovascular Risk Reduction Market by Country
Chapter 4. Europe Telmisartan Market by Distribution Channel
4.1 Europe Hospital Pharmacies Market by Country
4.2 Europe Drug Stores and Retail Pharmacies Market by Country
4.3 Europe Online Pharmacies Market by Country
Chapter 5. Europe Telmisartan Market by Country
5.1 Germany Telmisartan Market
5.1.1 Germany Telmisartan Market by Indication
5.1.2 Germany Telmisartan Market by Distribution Channel
5.2 UK Telmisartan Market
5.2.1 UK Telmisartan Market by Indication
5.2.2 UK Telmisartan Market by Distribution Channel
5.3 France Telmisartan Market
5.3.1 France Telmisartan Market by Indication
5.3.2 France Telmisartan Market by Distribution Channel
5.4 Russia Telmisartan Market
5.4.1 Russia Telmisartan Market by Indication
5.4.2 Russia Telmisartan Market by Distribution Channel
5.5 Spain Telmisartan Market
5.5.1 Spain Telmisartan Market by Indication
5.5.2 Spain Telmisartan Market by Distribution Channel
5.6 Italy Telmisartan Market
5.6.1 Italy Telmisartan Market by Indication
5.6.2 Italy Telmisartan Market by Distribution Channel
5.7 Rest of Europe Telmisartan Market
5.7.1 Rest of Europe Telmisartan Market by Indication
5.7.2 Rest of Europe Telmisartan Market by Distribution Channel
Chapter 6. Company Profiles
6.1 Abbott Laboratories
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.2 Aurobindo Pharma Limited
6.2.1 Company Overview
6.2.1 Financial Analysis
6.2.2 Regional Analysis
6.2.3 Research & Development Expense
6.2.4 Recent strategies and developments:
6.2.4.1 Approvals:
6.2.4.2 Acquisition and Mergers:
6.3 Boehringer Ingelheim International GmbH
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.3.5 Recent strategies and developments:
6.3.5.1 Approvals:
6.3.5.2 Partnerships, Collaborations, and Agreements:
6.4 Cipla Limited
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expense
6.4.5 Recent strategies and developments:
6.4.5.1 Partnerships, Collaborations, and Agreements:
6.4.5.2 Approvals:
6.5 GlaxoSmithKline PLC (GSK)
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Research & Development Expense
6.6 Mylan N.V.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Regional Analysis
6.6.4 Research & Development Expense
6.6.5 Recent strategies and developments:
6.6.5.1 Product Launches and Product Expansions:
6.7 Sanofi S.A.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Segmental and Regional Analysis
6.7.4 Research & Development Expense
6.8 Sun Pharmaceutical Industries Ltd.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expense
6.8.5 Recent strategies and developments:
6.8.5.1 Approvals:
6.8.5.2 Product Launches and Product Expansions:
6.9 Teva Pharmaceutical Industries Ltd.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Regional Analysis
6.9.4 Research & Development Expenses
6.9.5 Recent strategies and developments:
6.9.5.1 Approvals:
6.9.5.2 Product Launches and Product Expansions:
6.10. Cadila Healthcare Ltd. (Zydus Cadila)
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Segmental and Regional Analysis
6.10.4 Research & Development Expense
6.10.5 Recent strategies and developments:
6.10.5.1 Approvals:
TABLE 1 Europe Telmisartan Market, 2016 - 2019, USD Million
TABLE 2 Europe Telmisartan Market, 2020 - 2026, USD Million
TABLE 3 Europe Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 4 Europe Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 5 Europe Hypertension Market by Country, 2016 - 2019, USD Million
TABLE 6 Europe Hypertension Market by Country, 2020 - 2026, USD Million
TABLE 7 Europe Cardiovascular Risk Reduction Market by Country, 2016 - 2019, USD Million
TABLE 8 Europe Cardiovascular Risk Reduction Market by Country, 2020 - 2026, USD Million
TABLE 9 Europe Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 10 Europe Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 11 Europe Hospital Pharmacies Market by Country, 2016 - 2019, USD Million
TABLE 12 Europe Hospital Pharmacies Market by Country, 2020 - 2026, USD Million
TABLE 13 Europe Drug Stores and Retail Pharmacies Market by Country, 2016 - 2019, USD Million
TABLE 14 Europe Drug Stores and Retail Pharmacies Market by Country, 2020 - 2026, USD Million
TABLE 15 Europe Online Pharmacies Market by Country, 2016 - 2019, USD Million
TABLE 16 Europe Online Pharmacies Market by Country, 2020 - 2026, USD Million
TABLE 17 Europe Telmisartan Market by Country, 2016 - 2019, USD Million
TABLE 18 Europe Telmisartan Market by Country, 2020 - 2026, USD Million
TABLE 19 Germany Telmisartan Market, 2016 - 2019, USD Million
TABLE 20 Germany Telmisartan Market, 2020 - 2026, USD Million
TABLE 21 Germany Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 22 Germany Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 23 Germany Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 24 Germany Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 25 UK Telmisartan Market, 2016 - 2019, USD Million
TABLE 26 UK Telmisartan Market, 2020 - 2026, USD Million
TABLE 27 UK Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 28 UK Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 29 UK Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 30 UK Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 31 France Telmisartan Market, 2016 - 2019, USD Million
TABLE 32 France Telmisartan Market, 2020 - 2026, USD Million
TABLE 33 France Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 34 France Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 35 France Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 36 France Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 37 Russia Telmisartan Market, 2016 - 2019, USD Million
TABLE 38 Russia Telmisartan Market, 2020 - 2026, USD Million
TABLE 39 Russia Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 40 Russia Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 41 Russia Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 42 Russia Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 43 Spain Telmisartan Market, 2016 - 2019, USD Million
TABLE 44 Spain Telmisartan Market, 2020 - 2026, USD Million
TABLE 45 Spain Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 46 Spain Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 47 Spain Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 48 Spain Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 49 Italy Telmisartan Market, 2016 - 2019, USD Million
TABLE 50 Italy Telmisartan Market, 2020 - 2026, USD Million
TABLE 51 Italy Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 52 Italy Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 53 Italy Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 54 Italy Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 55 Rest of Europe Telmisartan Market, 2016 - 2019, USD Million
TABLE 56 Rest of Europe Telmisartan Market, 2020 - 2026, USD Million
TABLE 57 Rest of Europe Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 58 Rest of Europe Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 59 Rest of Europe Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 60 Rest of Europe Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 61 Key Information – Abbott Laboratories
TABLE 62 key information – Aurobindo Pharma Limited
TABLE 63 Key Information – Boehringer Ingelheim International GmbH
TABLE 64 Key Information – Cipla Limited
TABLE 65 Key Information – GlaxoSmithKline PLC (GSK)
TABLE 66 Key Information – Mylan N.V.
TABLE 67 Key Information – Sanofi S.A.
TABLE 68 Key Information – Sun Pharmaceutical Industries Ltd.
TABLE 69 Key Information – Teva Pharmaceuticals Industries Ltd.
TABLE 70 Key Information – Cadila Healthcare Ltd.
List of Figures
FIG 1 Methodology for the research